In MuSK‑positive myasthenia gravis, when should intravenous immunoglobulin (IVIG) be used and what is the recommended dosing schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IVIG for MuSK Myasthenia Gravis

For MuSK-positive myasthenia gravis with severe symptoms (Grade 3-4: dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms), administer IVIG at 2 g/kg divided over 5 days (0.4 g/kg/day), combined with corticosteroids and consider rituximab if refractory.

When to Use IVIG in MuSK-MG

Severity-Based Approach

Mild to Moderate Disease (Grade 2):

  • Start with pyridostigmine (30 mg PO three times daily, titrate to max 120 mg four times daily) and corticosteroids (prednisone 0.5-1 mg/kg/day orally) 1
  • Critical caveat: Cholinesterase inhibitors like pyridostigmine should be avoided in many MuSK-MG patients due to risk of clinical worsening and cholinergic crisis 2
  • IVIG is not typically first-line at this stage

Severe Disease (Grade 3-4):

  • Initiate IVIG immediately when patients have:
    • Limiting self-care requiring aids
    • Weakness limiting walking
    • ANY dysphagia
    • Facial weakness
    • Respiratory muscle weakness
    • Rapidly progressive symptoms 1, 3
  • Requires ICU-level monitoring capability
  • Permanent discontinuation of immune checkpoint inhibitors if applicable

Recommended IVIG Dosing Schedule

Standard Regimen

Total dose: 2 g/kg divided over 5 days (0.4 g/kg/day) 1, 3

Infusion protocol 4:

  • Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min)
  • If tolerated after 30 minutes, gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min)
  • Monitor vital signs throughout infusion

Alternative Dosing

  • 1-2 g/kg over 2 consecutive days (1 g/kg each day) for severe cases 5
  • Some evidence suggests low-dose IVIG (~1.0 g/kg cumulative) may provide comparable short-term improvement to standard 2 g/kg dosing, though this requires cautious interpretation 6

Combination Therapy Approach

Concurrent treatments with IVIG:

  1. Corticosteroids: Continue methylprednisolone 2-4 mg/kg/day or prednisone 1-1.5 mg/kg/day 1, 3

    • Begin steroid taper 3-4 weeks after initiation
  2. Plasmapheresis alternative: IVIG and plasmapheresis are equally effective 1, 3

    • Do not administer plasmapheresis immediately after IVIG as it will remove the immunoglobulin 1
  3. Rituximab for refractory cases: Add if no response to IVIG or plasmapheresis 1

    • Rituximab is particularly effective in MuSK-MG and increasingly used early in disease course 2

Clinical Evidence Specific to MuSK-MG

The evidence for IVIG in MuSK-MG comes primarily from case reports showing:

  • Clinical improvement observed 3 days after starting IVIG 7
  • Effect duration: 2-3 months per course 7
  • Potential for long-term effect exceeding 20 months in some patients 8
  • Effective when conventional treatments (thymectomy, steroids, tacrolimus) have failed 7

Monitoring Requirements

During acute treatment:

  • Frequent pulmonary function assessment (vital capacity, negative inspiratory force) 1, 3
  • Daily neurologic review 1
  • Monitor for thrombosis risk (especially in elderly, immobilized, or hypercoagulable patients) 4
  • Assess renal function in at-risk patients 4

Pre-infusion screening:

  • Check serum IgA levels (IgA deficiency increases anaphylaxis risk) 5
  • Use IgA-reduced preparations if deficiency detected

Important Caveats for MuSK-MG

  1. Avoid medications that worsen myasthenia: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides 1, 3

  2. MuSK-MG differs from AChR-positive MG:

    • Corticosteroids and non-steroidal immunosuppressants are less effective, requiring higher doses and prolonged treatment 2
    • Rituximab shows superior efficacy and should be considered early 2
  3. IVIG may be monophasic: Additional corticosteroid-sparing agents may not be required after successful IVIG treatment 3

  4. Maintenance therapy: If repeated courses needed, consider monthly IVIG (1-2 g/kg) for 1-6 months 5

Risk Mitigation

For patients at high risk (elderly, renal insufficiency, thrombosis risk):

  • Administer at minimum effective dose and slowest tolerable infusion rate 4
  • Ensure adequate hydration before administration 4
  • Monitor blood viscosity in hyperviscosity-prone patients 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.